EICHORCondition: Diffuse Astrocytoma, IDH-Wildtype · Recurrent Glioblastoma · Sponsor: National Cancer Institute (NCI)
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment (recurrent). Tocilizumab is a monoclonal antibody that binds to receptors for a protein called interleukin-6 (IL-6), which is made by white blood cells and other cells in the body as well as certain types of cancer. This may help lower the body's immune response and reduce inflammation. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Fractionated stereotactic radiation therapy uses special equipment to precisely deliver multiple, smaller doses of radiation spread over several treatment sessions to the tumor. The goal of this study is to change a tumor that is unresponsive to cancer therapy into a more responsive one. Therapy with fractionated stereotactic radiotherapy in combination with tocilizumab may suppress the inhibitory effect of immune cells surrounding the tumor and consequently allow an immunotherapy treatment by atezolizumab to activate the immune response against the tumor. Combination therapy with tocilizumab, atezolizumab and fractionated stereotactic radiation therapy may shrink or stabilize the cancer better than radiation therapy alone in patients with recurrent glioblastoma.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Kaiser Permanente-Anaheim | Anaheim, California, United States | — |
| Kaiser Permanente-Bellflower | Bellflower, California, United States | — |
| Kaiser Permanente Los Angeles Medical Center | Los Angeles, California, United States | — |
| Los Angeles General Medical Center | Los Angeles, California, United States | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| Kaiser Permanente-Ontario | Ontario, California, United States | — |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | — |
| Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville, California, United States | — |
| Sutter Roseville Medical Center | Roseville, California, United States | — |
| Sutter Medical Center Sacramento | Sacramento, California, United States | — |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| Kaiser Permanente-San Diego Zion | San Diego, California, United States | — |
+ 98 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04729959